- BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
-
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
- -
-
Paragraph 0204
(2019/03/30)
-
- As the NS4B inhibitor benzofuran analogs (by machine translation)
-
The present invention discloses a kind of as NS4B benzofuran analogue inhibitors, in particular to the formula (I) below or a pharmaceutically acceptable salt thereof. (by machine translation)
- -
-
Paragraph 0458; 0459; 0460; 0461; 0462; 0463
(2016/10/31)
-
- NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS
-
The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.
- -
-
Page/Page column 49-50
(2011/06/19)
-
- 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM
-
The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R 1 to R 4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders
- -
-
Page/Page column 107-108
(2010/06/17)
-
- TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE
-
A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or
- -
-
Page/Page column 16
(2008/12/06)
-
- ORGANIC COMPOUNDS
-
Compounds of formula (I) in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or
- -
-
Page/Page column 17
(2008/06/13)
-